Respiratory Disorders Treatment Market Size, Share, Growth & Trends Analysis Report by 2028

Respiratory Disorders Treatment Market

Respiratory Disorders Treatment Market - By Disease(Asthma, Chronic Obstructive Pulmonary Disease [COPD], Lung Cancer, Respiratory Tract Infection, Allergic Rhinitis, Cystic Fibrosis [CF]), By Drug Class (Bronchodilators, Combination Drugs, Immunotherapy, Corticosteroids, Antibiotics, CFTR, Target Therapy, and Immunotherapy), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Route of Administration (Oral, Nasal, and Injectable), And By Region- Global Industry Perspective, Comprehensive Analysis, and Forecast, 2021 – 2028

Category: Pharmaceutical Report Format : PDF Report Code: ZMR-6607 Published Date: Aug-2021 Status : Published
Market Size in 2020 Market Forecast in 2028 CAGR (in %) Base Year
USD 98.9 Billion USD 112.5 Billion 6.1% 2020

Respiratory Disorders Treatment Market

The global Respiratory Disorders Treatment Market accrued earnings worth approximately 98.9 USD Billion in 2020 and is predicted to gain revenue of about 112.5 USD Billion by 2028, is set to record a CAGR of nearly 6.1% over the period from 2021 to 2028. The report offers assessment and analysis of the Respiratory Disorders Treatment market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2020 along with a forecast from 2021 to 2028 based on revenue USD Billion.

Global Respiratory Disorders Treatment Market SizeRequest Free Sample

Respiratory Disorders Treatment Market: Outlook

Respiratory disorders are life-threatening health problems and classified under four categories such as acute disorders, chronic ailments, occupational lung diseases, and parenchymal lung ailments. Acute disorders include influenza and pneumonia, chronic ailments are asthma and chronic obstructive pulmonary disease, and occupational lung diseases include asbestosis, byssinosis, & coal worker’s pneumoconiosis. Additionally, parenchymal lung ailments encompass immune related lung disorders. Furthermore, various kinds of therapies are utilized for treating these respiratory disorders that include mind-body therapies, integrative modalities, pharmacotreatment, supplements, nutrition, and self-care strategies.

Additionally, respiratory disorders are both non-communicable & communicable that can prove to be fatal for patients and result in mortality, economic burden on patients, and disability adjusted life years. Asthma is one of the best examples of non-communicable respiratory ailment and tuberculosis is one of the most common communicable respiratory diseases. Today, most of chronic obstructive pulmonary disorders are treated through inhaled corticosteroids. Apart from this, chronic respiratory disorders can be treated with bronchodilator and antibiotics. Moreover, COVID-19 is being treated through Remdesivir inoculation, ingestion of Paracetamol, and plasma therapies.

Respiratory Disorders Treatment Market: Growth Drivers

Massive use of leukotriene blocking agents in treating asthma due to its proven efficacy and launching of new drugs for treating respiratory disorders will benefit growth of respiratory disorders treatment market. Apparently, rise in cases of lung transplantation in countries such as the U.S. and the UK is likely to aid respiratory disorders treatment industry expansion. Lung tissue repair & regeneration helps in rebuilding lungs after suffering damages from respiratory disorders. Large-scale use of mepolizumab and omalizumab for treating severe asthma to drive business landscape. This will further add towards growth of respiratory disorders treatment market over forthcoming years. Breakthroughs in drug development for treating respiratory disorders will embellish growth of respiratory disorders treatment industry during forecast period.

Furthermore, large-scale use of translational lung medicine for treating respiratory ailments will proliferate expansion of respiratory disorders treatment market. Rise in research on lung microbiome will help in new drug discovery for treating chronic respiratory illness, thereby providing lucrative growth avenues for respiratory disorders treatment industry. Increase in respiratory illness due to rise in pollution due to emissions from vehicles on roads along with rise in combined drug therapy for treating respiratory disorders will multiply development of respiratory disorders treatment industry.

Regional Landscape

North America To Contribute Substantially Towards Market Profitability By 2028

The regional market growth during forecast timeline can be attributed to cost-efficiency of interventions for chronic obstructive pulmonary disorders & asthma in countries such as the U.S. and Canada. In addition to this, chronic respiratory disorders are a huge burden for healthcare systems in the U.S. and this will enhance market penetration in the subcontinent.

Additionally, early risk diagnosis, preventive measures, participation of individuals & communities, and preemptive approaches will boost business growth trends. Development of advanced tools including RNA interference, cell-based approaches, tissue engineering, database sharing, high-throughput proteomics technologies, synthetic biology, imaging, microfluidics, and nanotechnology will steer regional market size.

Respiratory Disorders Treatment Market: Report Scope

Report Attributes Report Details
Report Name Respiratory Disorders Treatment Market Research Report
Market Size in 2020 USD 98.9 Billion
Market Forecast in 2028 USD 112.5 Billion
Growth Rate CAGR of 6.1%
Number of Pages -
Key Companies Covered Mylan N.V., GlaxoSmithKline plc, Novartis AG, Cipla, Roche Diagnostics, AstraZeneca plc, Sanofi, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries, CHIESI Farmaceutici S.p.A, and Vertex Pharmaceuticals Incorporated.
Segments Covered By Disease, By Drug Class, By Distribution Channel, By Route of Administration, And By Region
Regions Covered North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)
Base Year 2020
Historical Year 2016 to 2020
Forecast Year 2021 - 2028
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization

Competitive Landscape

Some of the leading in the global market include

  • Mylan N.V.
  • GlaxoSmithKline plc
  • Novartis AG
  • Cipla
  • Roche Diagnostics
  • AstraZeneca plc
  • Sanofi
  • Merck & Co.Inc.
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries
  • CHIESI Farmaceutici S.p.A
  • Vertex Pharmaceuticals Incorporated.  

The global Respiratory Disorders Treatment Market is segmented as follows:

By Disease

By Drug Class

  • Bronchodilators 
  • Corticosteroids
  • Combination Drugs
  • Antibiotics
  • Target Therapy
  • Immunotherapy
  • CFTR

By Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Route of Administration

  • Oral
  • Nasal
  • Injectable

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

FrequentlyAsked Questions

Massive use of leukotriene blocking agents in treating asthma due to its proven efficacy and launching of new drugs for treating respiratory disorders will benefit growth of respiratory disorders treatment market. Apparently, rise in cases of lung transplantation in countries such as the U.S. and the UK is likely to aid respiratory disorders treatment industry expansion. Lung tissue repair & regeneration helps in rebuilding lungs after suffering damages from respiratory disorders. Breakthroughs in drug development for treating respiratory disorders will embellish growth of respiratory disorders treatment industry during forecast period.

Furthermore, large-scale use of translational lung medicine for treating respiratory ailments will proliferate expansion of respiratory disorders treatment market. Surge in respiratory illness due to rise in pollution due to emissions from vehicles on roads along with rise in combined drug therapy for treating respiratory disorders will multiply development of respiratory disorders treatment industry.

According to Zion market research report, the global Respiratory Disorders Treatment market accrued earnings worth approximately 98.9 (USD Billion) in 2020 and is predicted to gain revenue of about 112.5(USD Billion) by 2028, is set to record a CAGR of nearly 6.1% over the period from 2021 to 2028.

North America will account notably towards the global market value over the estimated timeline. The regional market surge is subject to cost-efficiency of interventions for chronic obstructive pulmonary disorders & asthma in countries such as the U.S. and Canada. In addition to this, chronic respiratory disorders are a huge burden for healthcare systems in the U.S. and this will enhance market penetration in the sub-continent. Additionally, early risk diagnosis, preventive measures, participation of individuals & communities, and preemptive approaches will boost business growth trends. Development of advanced tools including RNA interference, cell-based approaches, tissue engineering, database sharing, high-throughput proteomic technologies, synthetic biology, imaging, microfluidics, and nanotechnology will steer regional market size.    

The key market participants include Mylan N.V., GlaxoSmithKline plc, Novartis AG, Cipla, Roche Diagnostics, AstraZeneca plc, Sanofi, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries, CHIESI Farmaceutici S.p.A, and Vertex Pharmaceuticals Incorporated.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed